Toronto Dominion Bank
LSB

Toronto Dominion Bank’s LakeShore Biopharma LSB Stock Holding History

Toronto Dominion Bank’s Portfolio LSB Stock Details LSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,048,320
Closed -$43K – 2011
2025
Q1 		$43K Buy
+1,048,320
New +$2.59M ﹤0.01% 1380

Other funds holding LSB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Superstring Capital Management New York $140M AUM 323.19% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Toronto Dominion Bank's LSB Position: Q2 2025 in Review

Toronto Dominion Bank sold out of LakeShore Biopharma (LSB) in Q2 2025, closing a stake of 1,048,320 shares — an estimated $43K sold.

Toronto Dominion Bank first reported a position in LSB in Q1 2025 and held it in 1 quarter. The position peaked at $43K in Q1 2025. 7 funds tracked by Wall St. Rank hold LSB as of Q2 2025.

  • Toronto Dominion Bank reported no remaining LakeShore Biopharma position as of Q2 2025 after selling out during the quarter.
  • Toronto Dominion Bank sold 1,048,320 LakeShore Biopharma shares in Q2 2025, an estimated $43K.
  • Toronto Dominion Bank first reported a position in LakeShore Biopharma in Q1 2025 and held it in 1 quarter.
  • Toronto Dominion Bank's LakeShore Biopharma position peaked at $43K in Q1 2025.
  • 7 funds tracked by Wall St. Rank held LakeShore Biopharma as of Q2 2025.

Based on Toronto Dominion Bank's 13F filing for Q2 2025, filed 14 Aug 2025.